6533b81ffe1ef96bd1277c5e
RESEARCH PRODUCT
Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice
Luis M. EstebanBelén Pastor-navarroJosé Rubio-brionesÁNgel Borque-fernandoJosé Antonio López-guerreroJosé Antonio López-guerreroJose Dominguez-escrigsubject
MaleOncologymedicine.medical_specialtyQH301-705.5clinical biomarkers030232 urology & nephrologyReviewIndependent predictorCatalysisInorganic Chemistry03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineDaily practicemedicineHumansBiology (General)Physical and Theoretical ChemistryOverdiagnosisWatchful WaitingQD1-999Molecular BiologyPathologicalSpectroscopybusiness.industryOrganic Chemistryactive surveillanceProstatic NeoplasmsCancerGeneral Medicinemedicine.diseaseprostate cancerComputer Science ApplicationsChemistryUrine biomarkers030220 oncology & carcinogenesisDisease Progressionrisk predictorsbusinessBiomarkersClinical progressiondescription
Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is currently based on PSA levels, which are associated with overdiagnosis and overtreatment. Moreover, most PCas are localized tumours; hence, many patients with low-/very low-risk PCa could benefit from active surveillance (AS) programs instead of more aggressive, active treatments. Heterogeneity within inclusion criteria and follow-up strategies are the main controversial issues that AS presently faces. Many biomarkers are currently under investigation in this setting; however, none has yet demonstrated enough diagnostic ability as an independent predictor of pathological or clinical progression. This work aims to review the currently available literature on tissue, blood and urine biomarkers validated in clinical practice for the management of AS patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-06-01 | International Journal of Molecular Sciences |